March 31 (Reuters) – Novo Nordisk has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off competition from cheaper ...

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams March 31 (Reuters) - Novo Nordisk on Tuesday cut the prices of its ...

A drug that helped turn Novo Nordisk into Europe's most valuable company is about to lose its monopoly grip across much of the globe. Patent protections on semaglutide—sold as Ozempic for diabetes and ...

The patent for semaglutide, the drug used in major weight-loss medications like Wegovy and Ozempic has expired. The end of the patent — held by Danish pharmaceutical giant Novo Nordisk — opens the ...

The expected arrival of generic versions of semaglutide -- the active ingredient in Ozempic and Wegovy -- is poised to force a rethink of how Canadian insurers handle obesity treatments. At present, ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Dany Lepage discusses the architectural ...

After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S.

Lifetime Access to This All-in-One PDF Suite Is Now 53% Off Edit, convert, OCR, and secure files for under $80 with this one-time, lifetime subscription deal.

Throughout the year, Teva had momentum in innovative medicines, scaling its global generics and biosimilars portfolio. On the brand side, Teva said it continued to showcase strong performance of its ...

Every shopper has faced the dilemma: do you grab the cheaper store brand or stick with the familiar name brand? With grocery prices climbing, the choice between saving money and ensuring quality feels ...

Highmark recently shared how it increased generic and biosimilar access to members, focusing on drugs for multiple sclerosis, cancer and autoimmune conditions. The insurer has been working with ...